TRAIL (TNF-Related Apoptosis-Inducing Ligand), also known as Apo2L, is a member of the TNF ligand family. TRAIl is a type II membrane protein which may be expressed as a full-length, cell surface associated protein as well as in a soluble form. Both surface and soluble forms of TRAIL rapidly induce apoptosis on a wide range of cell lines. TRAIL has been shown to cause apoptotic death in either tumorigenic or transformed cells, but not in normal cells. TRAIL-mediated apoptosis has been shown to involve the activation of caspases, and is blocked by over-expression of the caspase-1 protease inhibitor, CrmA. TRAIL has also been reported to induce the transcription factor NF-κB in a cell type-specific manner. Two cognate TRAIL receptors DR4, and DR5, as well as two decoy receptors, DcR1/TRID and DcR2/TRUNDD have been identified. TRAIL has been shown to be involved in T cell cytotoxicity, but the exact physiological role TRAIL plays in T-cell mediated cytotoxicity remains to be elucidated. The RIK-2 antibody recognizes human TRAIL. Human TRAIL cDNA was transferred to an expression vector and transfected into the 2PK-3 mouse B cell lymphoma cell line to generate stable transfectants, which were then used to immunize mice. The RIK-2 clone was selected based on its ability to block cytotoxic activity. TRAIL has been renamed as CD253 recently. Flow cytometric analysis of TRAIL. Profile of human TRAIL/2PK-3 cell line analyzed on a FACScan™
Flow Cytometry : Applications include flow cytometry (0.25-1.0 μg/1x10e6 cells). Blocking: The RIK-2 antibody is useful to block TRAIL-induced apoptosis. The no azide/low endotoxin format (NA/LE), Cat. No. 550912, is recommended for in vitro blocking assays.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
The antibody was conjugated with biotin under optimum conditions, and unreacted biotin was removed.
Stock
4 °C
Stockage commentaire
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Kayagaki, Yamaguchi, Nakayama, Kawasaki, Akiba, Okumura, Yagita: "Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 162, Issue 5, pp. 2639-47, (1999) (PubMed).
Mariani, Matiba, Armandola, Krammer: "Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells." dans: The Journal of cell biology, Vol. 137, Issue 1, pp. 221-9, (1997) (PubMed).
Sheridan, Marsters, Pitti, Gurney, Skubatch, Baldwin, Ramakrishnan, Gray, Baker, Wood, Goddard, Godowski, Ashkenazi: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors." dans: Science (New York, N.Y.), Vol. 277, Issue 5327, pp. 818-21, (1997) (PubMed).
Pitti, Marsters, Ruppert, Donahue, Moore, Ashkenazi: "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family." dans: The Journal of biological chemistry, Vol. 271, Issue 22, pp. 12687-90, (1996) (PubMed).
Wiley, Schooley, Smolak, Din, Huang, Nicholl, Sutherland, Smith, Rauch, Smith: "Identification and characterization of a new member of the TNF family that induces apoptosis." dans: Immunity, Vol. 3, Issue 6, pp. 673-82, (1996) (PubMed).
Antigène
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))